Breast

The CompassHER2 Trials Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer

CIRB #H-40381/ CTSU #EA1181 (CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients who Achieve a Pathologic Complete Response

CIRB #H-42687/ CTSU #A011801 (CompassHER2-RD): CompassHER2 Residual Disease РA Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared With T-DM1 and Tucatinib 

IRB #H-42223/ DFCI #19-239: Phase 1b/2 Study to Evaluate Safety and Anti-Tumor Activity of Antibody-Drug Conjugate Sacituzumab Govitecan in Combination with the Poly (Adenosine Diphosphate [ADP]-Ribose) Polymerase (PARP) Inhibitor Talazoparib in Patients with Metastatic Triple-Negative Breast Cancer

CIRB #H-42956/ ETCTN #10449: A Phase 1 Study of ZEN003694 in Combination with Binimetinib in Solid Tumors with RAS Pathway Alterations and Triple Negative Breast Cancer (pending IRB approval)

IRB #H-33188/ BMC #DOSI: Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging (DOSI)

IRB #H-37386/ CTSU #EA1151 (TMIST): Tomosynthesis Mammographic Imaging Screening Trial